In-House Versus Outsource: A Decision-Making Guide


The biologics market is quickly evolving from a focus on developing blockbuster drugs to exploring niche markets with unmet needs. While the changes are exciting, they pose several risks to a molecule’s success as competition intensifies, timelines shorten and capacity challenges emerge. Yesterday’s solutions may not be a perfect fit for today’s molecules.

Barry Rosenblatt, PhD President, SME Biotech Consulting
Dave Kenyon, PhD Vice President, Process Sciences Pharma Services Patheon, by Thermo Fisher Scientific